Page 112 - Read Online

Page 224 Jia et al. Cancer Drug Resist 2019;2:210-24 I http://dx.doi.org/10.20517/cdr.2018.010

2015;60:524-36.
123. Yim H. Current clinical trials with polo-like kinase 1 inhibitors in solid tumors. Anticancer Drugs 2013;24:999-1006.
124. Gjertsen BT, Schoffski P. Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy. Leukemia 2015;29:11-9.
125. Vijayaraghavan S, Moulder S, Keyomarsi K, Layman RM. Inhibiting CDK in cancer therapy: current evidence and future directions.
Target Oncol 2018;13:21-38.
126. Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 2009;9:153-66.
127. Cicenas J, Kalyan K, Sorokinas A, Jatulyte A, Valiunas D, et al. Highlights of the latest advances in research on CDK inhibitors. Cancers
(Basel) 2014;6:2224-42.
128. Carlson BA, Dubay MM, Sausville EA, Brizuela L, Worland PJ. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase
(CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res 1996;56:2973-8.
129. Zeidner JF, Karp JE. Clinical activity of alvocidib (flavopiridol) in acute myeloid leukemia. Leuk Res 2015;39:1312-8.
130. Blachly JS, Byrd JC, Grever M. Cyclin-dependent kinase inhibitors for the treatment of chronic lymphocytic leukemia. Semin Oncol
2016;43:265-73.
131. Kollareddy M, Zheleva D, Dzubak P, Brahmkshatriya PS, Lepsik M, et al. Aurora kinase inhibitors: progress towards the clinic. Invest
New Drugs 2012;30:2411-32.
132. Goldberg SL, Fenaux P, Craig MD, Gyan E, Lister J, et al. An exploratory phase 2 study of investigational Aurora A kinase inhibitor
alisertib (MLN8237) in acute myelogenous leukemia and myelodysplastic syndromes. Leuk Res Rep 2014;3:58-61.